Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)
23. Mai 2022 06:36 ET
|
Ocugen
MALVERN, Pa., May 23, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and...
COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety
08. Januar 2022 18:27 ET
|
Ocugen
Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared...
New Data Suggest COVAXIN™ (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
15. Dezember 2021 06:46 ET
|
Ocugen
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infectionImmune memory against conserved nucleoprotein may provide an added...
Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2
03. Mai 2021 07:30 ET
|
Ocugen
COVAXIN effectively neutralizes Brazil variant along with UK variant and India double mutant variantPotential effectiveness against multiple variants reduces the possibility of mutant virus...
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech shares Phase 3 Interim Results of COVAXIN, Demonstrates Efficacy of 81%
03. März 2021 08:00 ET
|
Ocugen
Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing...
Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 Vaccine, for the US Market
22. Dezember 2020 07:30 ET
|
Ocugen
Companies will co-develop inactivated vaccine candidate, COVAXIN™, to prevent COVID-19 infection in the US Builds upon the promising safety and immunogenicity data in the Phase 1 and Phase 2...